Tatva Chintan Pharma Chem Ltd is Rated Hold

1 hour ago

Share Via

Tatva Chintan Pharma Chem Ltd is rated 'Hold' by MarketsMojo, with this rating last updated on 18 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Current Rating and Its Significance

The 'Hold' rating assigned to Tatva Chintan Pharma Chem Ltd indicates a neutral stance for investors. It suggests that while the stock may not be an immediate buy, it is not a sell either. Investors are advised to maintain their existing positions and monitor the company’s performance closely. This rating reflects a balance of strengths and weaknesses across key evaluation parameters, which we explore in detail below.

Quality Assessment

As of 12 May 2026, the company holds an average quality grade. This assessment considers factors such as operational efficiency, profitability consistency, and management effectiveness. Despite some challenges in long-term growth, the company has demonstrated resilience with positive quarterly results. Notably, the latest quarter recorded net sales of ₹131.33 crores and a PBDIT of ₹25.48 crores, marking the highest levels achieved to date. The operating profit margin also reached a peak of 19.40%, signalling operational strength in recent months.

Valuation Perspective

Currently, Tatva Chintan Pharma Chem Ltd is considered very expensive in valuation terms. The stock trades at a price-to-book value of 4.1, which is a premium compared to its peers and historical averages. This elevated valuation reflects investor optimism but also warrants caution. The company’s return on equity (ROE) stands at a modest 2.4%, which does not fully justify the high valuation multiple. Investors should weigh this premium against the company’s growth prospects and profitability metrics.

Financial Trend Analysis

The financial trend for Tatva Chintan Pharma Chem Ltd is outstanding, highlighting strong recent performance despite some long-term growth concerns. Over the past year, the stock has delivered a remarkable return of 70.12%, while net profits surged by 129.2%. The company has declared positive results for two consecutive quarters, underscoring a recovery phase. However, operating profit growth over the last five years has been negative at an annualised rate of -21.04%, indicating challenges in sustaining long-term expansion. The PEG ratio of 0.7 suggests that the stock’s price growth is somewhat aligned with its earnings growth, offering a nuanced picture for investors.

Technical Outlook

From a technical standpoint, the stock exhibits a mildly bullish trend as of 12 May 2026. Short-term price movements show positive momentum, with a one-month gain of 9.15% and a three-month increase of 11.30%. However, the six-month performance reflects a decline of 12.54%, indicating some volatility. The stock’s day change on the latest trading session was -1.38%, suggesting a minor pullback. Investors should consider these technical signals alongside fundamental factors when making decisions.

Additional Considerations

Institutional investor participation has declined slightly, with a reduction of 0.69% in their stake over the previous quarter. Currently, institutional investors hold 6.81% of the company’s shares. This trend may reflect cautious sentiment among sophisticated market participants, who typically have greater resources to analyse company fundamentals. The company’s debt-to-equity ratio remains low at 0.05 times, indicating a conservative capital structure and limited financial risk.

Implications for Investors

For investors, the 'Hold' rating on Tatva Chintan Pharma Chem Ltd suggests a cautious approach. The company’s outstanding recent financial performance and positive technical signals are encouraging, yet the very expensive valuation and average quality grade temper enthusiasm. The mixed long-term growth trend and reduced institutional interest further underline the need for careful monitoring.

Investors should consider maintaining their current holdings while observing upcoming quarterly results and market developments. The stock’s premium valuation means that any deterioration in financial performance or market sentiment could lead to increased volatility. Conversely, sustained profit growth and operational improvements could support a re-rating in the future.

Summary

In summary, Tatva Chintan Pharma Chem Ltd’s current 'Hold' rating reflects a balanced view of its strengths and challenges. The company’s outstanding financial trend and mildly bullish technical outlook are offset by a very expensive valuation and average quality metrics. This rating advises investors to hold their positions and remain vigilant, assessing new data as it emerges to inform future investment decisions.

Key Metrics as of 12 May 2026

Mojo Score: 68.0 (Hold)
Market Capitalisation: Smallcap
Debt to Equity Ratio: 0.05 times
Operating Profit Growth (5 years annualised): -21.04%
Net Profit Growth (1 year): +52.92%
Return on Equity (ROE): 2.4%
Price to Book Value: 4.1
Stock Returns: 1D: -1.38%, 1M: +9.15%, 3M: +11.30%, 6M: -12.54%, 1Y: +70.12%
Institutional Holding: 6.81% (down 0.69% last quarter)

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE